MRP Under Process
Official PMBI MRP is being updated for catalog code 2856.
Locate Jan Aushadhi KendraClinical Overview
Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally twice daily (or once daily for extended-release forms) with meals to minimize gastrointestinal discomfort. Swallow whole with water.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Diarrhea, upper respiratory tract infection, nausea, headache, flatulence, vomiting. Rare/Severe: Boxed warning: Lactic acidosis; acute pancreatitis (including fatal hemorrhagic/necrotizing pancreatitis), severe disabling arthralgia, and bullous pemphigoid.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Lactic acidosis. Discontinue immediately and seek emergency care if persistent, severe abdominal pain radiating to the back (pancreatitis) occurs. Dose adjustment required in renal impairment based on eGFR.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered endocrinologist, diabetologist, or qualified physician before initiating, adjusting dosages of, or substituting any antidiabetic or hormonal medication.
Metformin Hydrochloride Prolonged-release 500mg + Glimepiride 2mg Tablets
Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.
Metformin Hydrochloride Sustained Release Tablets 1000 mg
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Metformin Hydrochloride Tablets 500mg
Metformin Hydrochloride is the foundational first-line biguanide oral antihyperglycemic agent on the WHO Model List of Essential Medicines. It activates AMP-activated protein kinase (AMPK) in the liver, suppressing mitochondrial respiratory chain complex I, thereby potently inhibiting hepatic gluconeogenesis and glycogenolysis, while stimulating peripheral glucose uptake into skeletal muscle and delaying intestinal glucose absorption. Does not stimulate beta-cell insulin secretion, having zero intrinsic hypoglycemia risk and promoting weight neutrality or mild weight loss. Indicated as the initial pharmacological drug of choice for type 2 diabetes mellitus in adults and children aged 10 and older, and off-label in polycystic ovary syndrome (PCOS).
Pioglitazone Tablets 30mg
Pioglitazone Hydrochloride (15 mg, 30 mg) is a thiazolidinedione (TZD) insulin sensitizer on the WHO Model List of Essential Medicines. It acts as a potent, selective agonist at peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptors, modulating the transcription of genes involved in glucose and lipid metabolism, substantially improving insulin sensitivity in skeletal muscle, liver, and adipose tissue, and preserving pancreatic beta-cell mass over time. Indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus.